JasgitC(Chugh)SachdevMD

Director, Breast and GYN Early Trials

Dr. Sachdev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
10510 N 92nd ST
Suite 200
Scottsdale, AZ 85258
Phone+1 480-323-1350

Fax+1 480-323-1359

University of TennesseeFellowship, Hematology and Medical Oncology, 2004 - 2007
Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Residency, Internal Medicine, 2001 - 2004
Dayanand Medical College Class of 2000

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

PubMed

6 citations
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu
Investigational New Drugs. 2023-06-01
9 citations
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Rebecca Arend, Jhalak Dholakia, Cesar Castro, Ursula Matulonis, Erika Hamilton
Gynecologic Oncology. 2023-05-01
4 citations
Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.
Harshan Ravi, Andres M Arias-Lorza, James R Costello, Hyo Sook Han, Daniel K Jeong
Radiology. Imaging Cancer. 2023-03-01

Lectures

Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Five Prime Therapeutics Presents Monotherapy Data from the Phase 1a/1b Trial of FPA150 in Patients with Advanced Solid Tumors at the 2019 ASCO Annual MeetingJune 1st, 2019
Dr. Jasgit Sachdev on What's on the Horizon for Ovarian CancerNovember 23rd, 2016
Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian CancerOctober 25th, 2016
Join now to see all